Biogen Idec Inc experimental drug is going to treat Alzheimer’s. According to the study and the experiment’s result this drug is going to significantly slow cognitive decline in patients with early and mild forms of the disease.

Alzheimer’s accounts for 60 to 70% of cases of dementia. The most common symptoms are difficult remembering events, language problems, mood swings etc. Till date there is no such medicine which can cure the disease but medical science has not even produced a drug which can slower the disease’s development.

The drug is believed to reduce the brain destroying amyloid plague. Alzheimer’s is caused by these plagues in the brain and it plays a prominent role in the development of the disease.

The drug which is said to cure Alzheimer’s is aducanumab.

Alzheimer’s affects 15 million people worldwide, a number that is expected to grow to 75 million by 2030 without effective treatments. These treatments are very expensive so most people go for cost effective treatments which show only temporary results.

Alfred Sandrock, Biogen’s chief medical officer said that it is for the first time that an experimental drug has shown significant reduction in amyloid plague and also slowing impairments in patients with mild disease.

The second trial involved 166 people with mild to severe Alzeimers. They were divided into five groups four of them received different dose and the fifth received placebo. The results showed that all the participants showed better improvement than the ones who took placebo.

The experts are getting ready for the third trial later this year and based on the results the drug will be given approval.